Participants were randomly assigned to either pause their BTKi drug for three weeks (one week before and ... More information ...

Bayer BAYRY announced that the FDA has granted full approval to oncology drug, Vitrakvi (larotrectinib), a first-in-class TRK ...

The approval of the first kinase inhibitor, imatinib, for the treatment of chronic myelogenous leukemia (CML) in 2001 and the success of antibody-based drugs that targeted the epidermal growth ...

Results of the Phase III HERCULES trial suggest the first potential treatment option for a form of multiple sclerosis.